OrganOx

BGF has announced a landmark exit from OrganOx, a prominent medtech company, as part of its strong investment and exit activity in 2025. This transaction, valuing OrganOx at $1.5 billion, delivered £175 million in proceeds to BGF and is noted as one of the largest medtech exits on record in the UK.

Summary of transaction details:

• Value: Approximately £1.2 billion (USD $1.5 billion)
• Sector: Healthcare & Biotech (Medtech)
• Advisor: Not disclosed
• Key Entities: OrganOx (Target), BGF (Exiting Investor), Undisclosed Acquirer
• Location: UK (as a UK Medtech exit)

Note: This exit marks BGF’s largest-ever return, demonstrating the significant value creation achieved through its long-term investment strategy in the growth capital sector, particularly within innovative healthcare technologies.